Brain and Central Nervous System Tumors Clinical Trial
Official title:
Study of Outcome of Children Previously Enrolled in European Trials of Treatment for Primitive Neuroectodermal Tumour (PNET)
Verified date | April 2006 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Observational |
RATIONALE: Questionnaires that measure quality of life may improve the ability to plan
treatment for patients with primitive neuroectodermal tumors.
PURPOSE: This phase III trial is studying quality of life in patients who have undergone
previous treatment for primitive neuroectodermal tumors.
Status | Active, not recruiting |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 3 Years to 24 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Surviving primitive neuroectodermal tumor (PNET) patients previously enrolled in International Pediatric Oncology Society (SIOP) 2 or 3 phase III treatment trials - Surviving PNET patients eligible for and treated according to PNET 3 protocol but not randomized - No metastatic disease at time of allocation to treatment - No current progressive disease PATIENT CHARACTERISTICS: - No patient deemed unsuitable for this study by treating clinician PRIOR CONCURRENT THERAPY: - Not specified |
N/A
Country | Name | City | State |
---|---|---|---|
Ireland | Our Lady's Hospital for Sick Children | Dublin | |
United Kingdom | Royal Aberdeen Children's Hospital | Aberdeen | Scotland |
United Kingdom | Royal Belfast Hospital for Sick Children | Belfast | Northern Ireland |
United Kingdom | Birmingham Children's Hospital | Birmingham | England |
United Kingdom | Institute of Child Health at University of Bristol | Bristol | England |
United Kingdom | Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust | Cambridge | England |
United Kingdom | Childrens Hospital for Wales | Cardiff | Wales |
United Kingdom | Royal Hospital for Sick Children | Edinburgh | Scotland |
United Kingdom | Royal Hospital for Sick Children | Glasgow | Scotland |
United Kingdom | Leeds Cancer Centre at St. James's University Hospital | Leeds | England |
United Kingdom | Leicester Royal Infirmary | Leicester | England |
United Kingdom | Royal Liverpool Children's Hospital, Alder Hey | Liverpool | England |
United Kingdom | Great Ormond Street Hospital for Children NHS Trust | London | England |
United Kingdom | Royal London Hospital | London | England |
United Kingdom | Central Manchester and Manchester Children's University Hospitals NHS Trust | Manchester | England |
United Kingdom | Sir James Spence Institute of Child Health | Newcastle-Upon-Tyne | England |
United Kingdom | Queen's Medical Centre | Nottingham | England |
United Kingdom | Oxford Radcliffe Hospital | Oxford | England |
United Kingdom | Children's Hospital - Sheffield | Sheffield | England |
United Kingdom | Southampton General Hospital | Southampton | England |
United Kingdom | Royal Marsden NHS Foundation Trust - Surrey | Sutton | England |
Lead Sponsor | Collaborator |
---|---|
Children's Cancer and Leukaemia Group |
Ireland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of life (QOL) as measured by QOL questionnaire | |||
Secondary | Quality of survival compared among children undergoing different treatments by Health Utilities Index |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 |